GT201600086A - Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio - Google Patents

Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio

Info

Publication number
GT201600086A
GT201600086A GT201600086A GT201600086A GT201600086A GT 201600086 A GT201600086 A GT 201600086A GT 201600086 A GT201600086 A GT 201600086A GT 201600086 A GT201600086 A GT 201600086A GT 201600086 A GT201600086 A GT 201600086A
Authority
GT
Guatemala
Prior art keywords
pirrolo
triazins
useful
treat infections
respiratory synctial
Prior art date
Application number
GT201600086A
Other languages
English (en)
Spanish (es)
Inventor
Michael Oneil Hanrahan Clarke
Edgard Doerffler
Richard L Mackman
Dustin Siegel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201600086(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of GT201600086A publication Critical patent/GT201600086A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
GT201600086A 2013-11-11 2016-05-11 Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio GT201600086A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361902544P 2013-11-11 2013-11-11

Publications (1)

Publication Number Publication Date
GT201600086A true GT201600086A (es) 2018-01-17

Family

ID=52003049

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201600086A GT201600086A (es) 2013-11-11 2016-05-11 Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio

Country Status (36)

Country Link
US (5) US9388208B2 (enExample)
EP (3) EP3505173B1 (enExample)
JP (7) JP6234571B2 (enExample)
KR (4) KR102113705B1 (enExample)
CN (3) CN110003215B (enExample)
AP (1) AP2016009186A0 (enExample)
AU (5) AU2014346665A1 (enExample)
BR (1) BR112016010261B1 (enExample)
CA (1) CA2928674C (enExample)
CL (1) CL2016001120A1 (enExample)
CR (1) CR20160220A (enExample)
CU (1) CU20160065A7 (enExample)
CY (1) CY1121948T1 (enExample)
DK (2) DK3068405T3 (enExample)
DO (1) DOP2016000107A (enExample)
EA (2) EA029712B1 (enExample)
ES (2) ES2926155T3 (enExample)
GT (1) GT201600086A (enExample)
HR (2) HRP20220920T1 (enExample)
HU (2) HUE044960T2 (enExample)
IL (1) IL245324B (enExample)
LT (2) LT3068405T (enExample)
MD (1) MD4596C1 (enExample)
MX (2) MX376186B (enExample)
MY (2) MY182986A (enExample)
NZ (1) NZ719592A (enExample)
PE (1) PE20160670A1 (enExample)
PH (1) PH12016500867A1 (enExample)
PL (2) PL3068405T3 (enExample)
PT (2) PT3505173T (enExample)
SG (1) SG11201603427XA (enExample)
SI (2) SI3068405T1 (enExample)
TR (1) TR201910961T4 (enExample)
UA (1) UA119050C2 (enExample)
WO (1) WO2015069939A1 (enExample)
ZA (1) ZA201603123B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
MA34470B1 (fr) 2010-07-22 2013-08-01 Gilead Sciences Inc Procédés et composés pour traiter des infections à virus paramyxoviridae
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
PE20170698A1 (es) 2014-09-26 2017-06-05 Riboscience Llc Derivados de nucleosidos sustituidos con 4'-vinilo como inhibidores de la replicacion del arn del virus respiratorio sincitial
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
MX394858B (es) 2015-09-16 2025-03-24 Gilead Sciences Inc Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae
RU2720811C2 (ru) * 2015-09-23 2020-05-13 Мерк Шарп И Доум Лимитед 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы и их получение
AU2017231824B2 (en) 2016-03-09 2021-07-01 Alios Biopharma, Inc. Acyclic antivirals
CA3056072C (en) * 2017-03-14 2022-08-23 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
KR20190141747A (ko) 2017-05-01 2019-12-24 길리애드 사이언시즈, 인코포레이티드 (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
EP4512475A3 (en) 2017-07-11 2025-05-14 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
AU2018332540B2 (en) 2017-09-18 2023-10-05 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN109748921B (zh) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN108787177B (zh) * 2018-08-07 2024-03-15 中南大学 淤浆法制备黄原酸盐的方法及系统
US12234255B2 (en) 2019-05-14 2025-02-25 Regents Of The University Of Michigan Methods for glycosylation
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI775313B (zh) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) * 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI791193B (zh) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的一种新合成方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
JP7664287B2 (ja) 2020-05-29 2025-04-17 ギリアード サイエンシーズ, インコーポレイテッド レムデシビル治療方法
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
AU2021296841B2 (en) 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
LT4192839T (lt) 2020-08-06 2025-11-25 Remdesiviro tarpiniai junginiai
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ, インコーポレイテッド リン脂質化合物及びその使用
KR20250111239A (ko) 2020-08-27 2025-07-22 길리애드 사이언시즈, 인코포레이티드 바이러스 감염 치료를 위한 화합물 및 방법
TW202344257A (zh) * 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CN113880846B (zh) * 2020-12-31 2022-10-14 山东诚汇双达药业有限公司 一种7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的制备方法
KR20230170745A (ko) * 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250170155A1 (en) 2021-08-20 2025-05-29 Shionogi & Co., Ltd. Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action
CA3244278A1 (en) 2022-03-02 2023-09-07 Gilead Sciences Inc COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
WO2023168254A1 (en) * 2022-03-03 2023-09-07 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
MX2024010671A (es) 2022-03-03 2024-09-11 Gilead Sciences Inc Compuestos antivirales y metodos de elaboracion y uso de los mismos.
US20240309028A1 (en) 2023-02-16 2024-09-19 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2025049699A1 (en) 2023-08-31 2025-03-06 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2025049493A1 (en) 2023-08-31 2025-03-06 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
TW202517647A (zh) 2023-09-28 2025-05-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
EP1411954B1 (en) * 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
EP2114980B1 (en) 2007-01-12 2012-06-27 BioCryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2155758B1 (en) * 2007-05-10 2012-08-22 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro[3,4-d]dioxolane compounds for use in the treatment of viral infections and cancer
EP2019519B1 (en) 2007-07-25 2011-07-06 Nokia Siemens Networks Oy Method for addressing ethernet streams with a structured GPON GEM Port ID
CN102046626A (zh) 2008-04-23 2011-05-04 吉里德科学公司 用于抗病毒治疗的carba-核苷类似物
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
KR20180006499A (ko) * 2009-09-21 2018-01-17 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료용 2'―플루오로 치환된 카바-뉴클레오사이드 유사체
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
PH12013500033A1 (en) 2010-07-19 2017-07-26 Gilead Sciences Inc Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
MA34470B1 (fr) 2010-07-22 2013-08-01 Gilead Sciences Inc Procédés et composés pour traiter des infections à virus paramyxoviridae
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之2’-氟取代之碳-核苷類似物
AU2011306066B2 (en) * 2010-09-20 2015-01-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療c型肝炎病毒(hcv)之方法
WO2012142075A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
SI2794627T1 (sl) * 2011-12-22 2019-02-28 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
JP6242378B2 (ja) * 2012-03-13 2017-12-06 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス処置のための2’−置換カルバヌクレオシド類似体
HK1207647A1 (en) 2012-10-08 2016-02-05 Idenix Pharmaceuticals Llc 2'-chloro nucleoside analogs for hcv infection
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
AU2017232039A1 (en) 2017-10-12
AU2017232039B2 (en) 2019-03-28
EP3505173A1 (en) 2019-07-03
BR112016010261B1 (pt) 2022-02-08
US9388208B2 (en) 2016-07-12
CY1121948T1 (el) 2020-10-14
HRP20191303T1 (hr) 2019-10-18
CN110003215B (zh) 2021-12-17
CN105899216B (zh) 2019-03-05
CA2928674A1 (en) 2015-05-14
CU20160065A7 (es) 2016-09-30
ES2926155T3 (es) 2022-10-24
SI3068405T1 (sl) 2019-08-30
HUE044960T2 (hu) 2019-12-30
MY182986A (en) 2021-02-05
PT3068405T (pt) 2019-08-05
US20190055253A1 (en) 2019-02-21
WO2015069939A1 (en) 2015-05-14
JP2018070658A (ja) 2018-05-10
EA029712B1 (ru) 2018-05-31
AU2014346665A1 (en) 2016-05-19
KR102113705B1 (ko) 2020-05-21
KR101864973B1 (ko) 2018-06-05
JP2022088661A (ja) 2022-06-14
MD4596B1 (ro) 2018-10-31
US20250236623A1 (en) 2025-07-24
MX2016006066A (es) 2016-08-12
TR201910961T4 (tr) 2019-08-21
IL245324A0 (en) 2016-06-30
JP2024041986A (ja) 2024-03-27
US10377761B2 (en) 2019-08-13
EA039734B1 (ru) 2022-03-04
CA2928674C (en) 2018-10-02
BR112016010261A2 (enExample) 2017-08-08
JP7247155B2 (ja) 2023-03-28
JP2017502925A (ja) 2017-01-26
AU2023202506A1 (en) 2023-05-11
AU2017232039C1 (en) 2019-07-25
IL245324B (en) 2018-08-30
PE20160670A1 (es) 2016-07-10
AP2016009186A0 (en) 2016-04-30
JP2020055855A (ja) 2020-04-09
ES2743619T3 (es) 2020-02-20
KR20200057103A (ko) 2020-05-25
EP3068405A1 (en) 2016-09-21
US9701682B2 (en) 2017-07-11
AU2021201554B2 (en) 2023-02-02
CN114085243A (zh) 2022-02-25
MD4596C1 (ro) 2019-05-31
MX376186B (es) 2025-03-07
CN105899216A (zh) 2016-08-24
SI3505173T1 (sl) 2022-09-30
HRP20220920T1 (hr) 2022-10-28
EP3068405B1 (en) 2019-05-01
PT3505173T (pt) 2022-11-18
JP6393380B2 (ja) 2018-09-19
JP2018021051A (ja) 2018-02-08
PH12016500867A1 (en) 2016-06-20
ZA201603123B (en) 2019-08-28
DOP2016000107A (es) 2016-06-15
KR20210046833A (ko) 2021-04-28
PL3068405T3 (pl) 2019-10-31
HUE059683T2 (hu) 2022-12-28
KR20180059958A (ko) 2018-06-05
MD20160063A2 (ro) 2016-11-30
EP4122932A1 (en) 2023-01-25
KR102243724B1 (ko) 2021-04-23
KR20160074011A (ko) 2016-06-27
CR20160220A (es) 2016-07-22
MX2020010628A (es) 2020-10-22
US20150133395A1 (en) 2015-05-14
AU2019204381A1 (en) 2019-07-11
US20180016280A1 (en) 2018-01-18
SG11201603427XA (en) 2016-05-30
AU2021201554A1 (en) 2021-04-01
DK3505173T3 (da) 2022-08-22
JP7054394B2 (ja) 2022-04-13
LT3505173T (lt) 2022-10-10
MY197933A (en) 2023-07-25
EP3505173B1 (en) 2022-07-06
EA201792639A1 (ru) 2018-09-28
AU2019204381B2 (en) 2021-04-01
UA119050C2 (uk) 2019-04-25
CN114085243B (zh) 2024-04-26
NZ719592A (en) 2017-12-22
JP2021046413A (ja) 2021-03-25
PL3505173T3 (pl) 2022-10-17
JP6234571B2 (ja) 2017-11-22
US20170008897A1 (en) 2017-01-12
DK3068405T3 (da) 2019-07-29
LT3068405T (lt) 2019-08-12
AU2023202506B2 (en) 2025-01-23
EA201690978A1 (ru) 2016-09-30
CL2016001120A1 (es) 2017-05-05
US10059716B2 (en) 2018-08-28
CN110003215A (zh) 2019-07-12
KR102355881B1 (ko) 2022-01-25

Similar Documents

Publication Publication Date Title
GT201600086A (es) Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio
BR112016023558A2 (pt) compostos úteis como imunomoduladores
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
MX2017001284A (es) Tieno [3,2-d] pirimidina, furo[3,2-d] pirimidina y pirrolo [3,2-d] pirimidinas utiles para el tratamiento de infecciones por virus sincitial respiratorio.
MX381488B (es) Indoles para su uso en la infección por el virus de la gripe.
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
GT201500247A (es) Imidazopiridazinas sustituidas
NZ728707A (en) 2’-chloro aminopyrimidinone and pyrimidine dione nucleosides
DOP2016000278A (es) Nuevos compuestos macrocíclicos
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
UY36938A (es) Nuevos compuestos macrocíclicos modificados
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
UY36221A (es) Derivados de isoindolinona
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
UY36923A (es) Nuevos compuestos macrocíclicos de sulfondiimina
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório
CL2017002304A1 (es) Métodos para tratar enfermedades
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"
AR095353A1 (es) Compuesto
MX2016001858A (es) Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio.
EA201301016A1 (ru) Применение дитиин-тетракарбоксимидов в качестве репеллентов для птиц